Clinical Trial

Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

Completed
View on ClinicalTrials.gov →
Summary
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-06
notable Enrollment increased: 300 -> 338 participants 2026-08-06
notable Primary completion moved earlier: 2026-12-31 -> 2026-07-31 2026-08-06
minor Completion moved earlier: 2026-12-31 -> 2026-07-31 2026-08-06
Trial Details
NCT Number NCT04535882
Lead Sponsor Showa Inan General Hospital
Conditions LRG Levels
Enrollment 673 participants
Start Date 2020-10-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07